Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24
08 avr. 2024 11h15 HE
|
Imbria Pharmaceuticals Inc.
– Improvements in both patient-reported symptoms of heart failure and ventilatory efficiency during exercise testing were demonstrated – – Results support initiation of the Phase 3 FORTITUDE-HCM...
SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators
07 juil. 2020 08h30 HE
|
ARCA biopharma, Inc.
Integrin A5 may be a new target for intervening in the cell infectious processFindings may lead to the development of precision therapeutic approaches to prevent SARS-CoV-2-cell entry while preserving...
BioSig Announces Submission of FDA 510(k) Application for PURE EP™ System
28 mars 2018 02h00 HE
|
BioSig Technologies, Inc.
SANTA MONICA, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB:BSGM) announced that the Company has filed 510(k) application to the U.S. Food and Drug Administration (FDA)...
JACC: Clinical Electrophysiology Manuscript Featuring BioSig’s PURE EP System in Top Five Most Influential of 2016
21 févr. 2017 08h00 HE
|
BioSig Technologies, Inc.
Minneapolis, MN, Feb. 21, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to...
JACC: Clinical Electrophysiology Manuscript Featuring BioSig’s PURE EP System in Top Five Most Influential of 2016
19 févr. 2017 20h00 HE
|
BioSig Technologies, Inc.
MINNEAPOLIS, Feb. 20, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB:BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an...
BioSig Technologies’ PURE EP System Featured in The Journal of the American College of Cardiology: Clinical Electrophysiology
11 janv. 2017 08h00 HE
|
BioSig Technologies, Inc.
Minneapolis, MN, Jan. 11, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary technology platform designed to improve the $4 billion...